|
A011202
|
---
|
A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH
NODE DISSECTION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE
SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
|
| |
|
A022101
|
---
|
A PRAGMATIC RANDOMIZED PHASE III TRIAL EVALUATING TOTAL ABLATIVE THERAPY FOR PATIENTS WITH LIMITED METASTATIC COLORECTAL CANCER: EVALUATING RADIATION, ABLATION, AND SURGERY [ERASUR]
|
| |
|
A022104
|
---
|
THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
|
| |
|
A221702
|
---
|
ARM: AXILLARY REVERSE MAPPING – A PROSPECTIVE TRIAL TO STUDY RATES OF LYMPHEDEMA AND REGIONAL RECURRENCE AFTER SENTINEL LYMPH NODE BIOPSY AND SENTINEL LYMPH NODE BIOPSY FOLLOWED BY AXILLARY LYMPH NODE DISSECTION WITH AND WITHOUT AXILLARY REVERSE MAPPING
|
| |
|
A221803
|
---
|
MEPITEL FILM FOR THE REDUCTION OF RADIATION DERMATITIS IN BREAST CANCER PATIENTS UNDERGOING POST MASTECTOMY RADIATION THERAPY : A RANDOMIZED PHASE III CLINICAL TRIAL.
|
| |
|
A031701
|
---
|
A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
|
| |
|
A032002
|
---
|
PHASE II RANDOMIZED TRIAL OF ATEZOLIZUMAB VERSUS ATEZOLIZUMAB AND RADIATION THERAPY FOR PLATINUM INELIGIBLE/REFRACTORY METASTATIC UROTHELIAL CANCER (ART)
|
| |
|
A082002
|
---
|
A RANDOMIZED PHASE II/III TRIAL OF MODERN IMMUNOTHERAPY BASED SYSTEMIC THERAPY WITH OR WITHOUT SBRT FOR PD-L1-NEGATIVE, ADVANCED NON-SMALL CELL LUNG CANCER
|
| |
|
ABTC - 1604
|
---
|
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters.
|
| |